On Wednesday, in the course of current trade, Shares of Radian Group Inc (NYSE:RDN), climbed 2.65%, and is now trading at $ 18.21.
Radian Group, declared an improved support structure to focus solely on its credit union customers. The new approach comprises the addition of two national account managers and dedicated inside sales account administration team. This enriched group will ensure that Radian is providing firm support to meet the unique needs of credit unions, their members and their trade associations.
As part of this declaration, Radian is happy to welcome Bill Walker and David Mills as national account managers. Bill Walker joins Radian from another private mortgage insurance company where he was the national sales manager. David Mills joins Radian from Lake Michigan Federal Credit Union where he was the credit union correspondent lending manager.
Radian Group Inc., through its auxiliaries, provides mortgage and real estate products and services in the United States. It operates through two segments, Mortgage Insurance, and Mortgage and Real Estate Services (MRES). The Mortgage Insurance segment provides credit-related insurance coverage, principally through private mortgage insurance that protects mortgage lenders from all or a portion of default-related losses on residential mortgage loans made to home buyers, in addition to facilitates the sale of these mortgage loans in the secondary mortgage market.
During an Afternoon trade, Shares of Kite Pharma Inc (NASDAQ:KITE), dipped - 3.26%, and is now trading at $ 57.30.
Kite Pharma, declared clinical biomarker data from patients with relapsed/refractory B cell malignancies treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in a poster presentation during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), which is taking place in Chicago. In an ongoing Phase 1 clinical trial at the National Cancer Institute (NCI), being conducted under a Cooperative Research and Development Agreement (CRADA) between Kite Pharma and the NCI, patients with diverse B cell tumors are conditioned with cyclophosphamide and fludarabine, then dosed with their own T cells genetically modified to express a CAR designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. As stated at last year’s ASCO meeting, 76% of evaluable patients (N=29) achieved an overall response rate in this study. In this updated biomarker analysis, conditioning chemotherapy was associated with a noteworthy rise in homeostatic cytokines and chemokines, which could favor expansion, activation, and trafficking of CAR T cells. In addition, the recovery of B cells was seen in 7 of 12 patients with ongoing response duration greater than 12 months.
David Chang, M.D., Ph.D., Kite Pharma’s Executive Vice President, Research and Development, and Chief Medical Officer, and an author on the poster, commented, “The results being stated at ASCO provide additional key insights and further deepen our understanding of CAR T-cell therapy. We will continue to investigate biomarkers that may predict the clinical outcome in our ongoing KTE-C19 (anti-CD19 CAR T) clinical program which initiated patient dosing last month.”
Kite Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptors (CAR)-based therapy that is in Phase 1-2a clinical trials for the treatment of patients with refractory diffuse large B cell lymphoma.
Shares of Quest Diagnostics Inc (NYSE:DGX), during its Wednesday’s current trading session raised 0.50%, and is now trading at $ 74.06.
The percentage of American workers testing positive for illicit drugs such as marijuana, cocaine and methamphetamine has raised for the second successive year in the general U.S. workforce, according to insights from more than 10 million workplace drug test results released by Quest Diagnostics (DGX), the world’s leading provider of diagnostic information services. The analysis suggests a potential reversal in the decades’ long decline in the abuse of illicit drugs in the United States workforce.
The Quest Diagnostics Drug Testing Index (DTI) shows that the positivity rate for about 6.6 million urine drug tests in the general U.S. workforce raised overall by 9.3 percent, to 4.7 percent in 2014 contrast to 4.3 percent in 2013. 2013 was the first year since 2003 in which the overall positivity rate for urine drug tests raised in the general U.S. workforce. In addition, overall positivity for oral fluid and hair drug tests, representing about 1.1 million tests, raised between 2013 and 2014 in the general U.S. workforce.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, in addition to related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry.
Finally, Microchip Technology Inc. (NASDAQ:MCHP), gained 1.11% Wednesday, hitting its highest level.
Microchip Technology, declared from the Sensors Expo a combined analog and digital current sensor-the PAC1921. This new device is the world’s first high-side current sensor with both a digital output, in addition to a configurable analog output that can present power, current or voltage over the single output pin. Simultaneously, all power related output values are also accessible over the 2-Wire digital bus, which is compatible with I2C. The PAC1921, accessible in a 10-lead 3×3 mm VDFN package, was designed with the 2-Wire bus to maximize data and diagnostic reporting, while having the analog output to minimize data latency. The analog output can also be adjusted for use with 3V, 2V, 1.5V or 1V microcontroller inputs.
The PAC1921 is ideal for networking, power-distribution, power-supply, computing and industrial-automation applications that cannot allow for latency when performing high-speed power administration. A 39-bit accumulation register and 128 times gain configuration make this device ideal for both heavy and light system-load power measurement, from 0V to 32V. It has the ability to integrate more than two seconds of power-consumption data. Additionally, the PAC1921 has a READ/INT pin for host control of the measurement period; and this pin can be used to synchronize readings of multiple devices.
Microchip Technology Incorporated develops, manufactures, and sells semiconductor products for various embedded control applications. The company offers microcontrollers, such as 8-bit, 16-bit, and 32-bit microcontrollers under the PIC brand name; and 16-bit dsPIC digital signal controllers, in addition to provides microcontrollers for automotive networking, computing, lighting, power supplies, wireless communication, and wireless audio applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
